Impressive IOP results from second-generation microinvasive surgery
February 15th 2016Implantation of two second-generation trabecular micro-bypass stents (iStent inject, Glaukos) as a single procedure or combined with cataract surgery is a safe and effective option for reducing IOP and the medication burden in eyes with open-angle glaucoma and IOP uncontrolled by medication and/or surgery, according to German surgeons.
The AAO's preferred practice patterns for AMD
February 15th 2016High-level evidence supports the use of anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (AMD), but falls short of recommending any one agent over another in terms of efficacy or safety, said Paul Sternberg Jr., MD.
Surgical gene therapy study for wet AMD yields mixed results
February 15th 2016In a phase IIa study of patients with neovascular age-related macular degeneration, a single subretinal injection of rAAV.sFlt-1 gene therapy demonstrated acceptable safety, but not a complete or durable anti-VEGF response. Additional preclinical research is under way.
Photoactivation holds promise for keratitis treatment
February 11th 2016The same photoactivation process used in collagen cross-linking for keratoconus can kill bacteria without the need for the oxygen responsible for the biomechanical effects, potentially pointing toward better treatments for keratitis, according to Olivier Richoz, MD, PhD.
Lifeless limbus: What's the diagnosis?
February 1st 2016Ophthalmology Times is pleased to announce Amelia Fong, MD, of Georgetown University School of Medicine, Washington, DC, as the second-place winner of the publication’s 2015 Resident Writer’s Award Program, sponsored by Allergan. Dr. Fong’s entry is featured here.
Advances for refractive laser surgery aim to boost outcomes
February 1st 2016Refractive laser platforms provide outstanding results, have reliable technology with excellent predictability and outcomes, and provide a broad range of applications. Better diagnostic imaging is possible with optical coherence tomography and Scheimpflug technology, and the advances of femtosecond lasers are moving into cataract surgery, said Michael Mrochen, PhD.
Dr. David Apple's legacy endures through laboratory
February 1st 2016Were he alive today, he would likely feel heartened by how his work has been carried on by Gerd U. Auffarth, MD, FEBO, who is now director of The David J Apple International Laboratory for Ocular Pathology at the University of Heidelberg, Germany.